The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M) an increase of 18% on
the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s
prostate cancer imaging product Illuccix®.
U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth
between Q3 2023 and Q4 2023.
Ann: Telix Q1 2024 Revenue and Business Update, page-2
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.58 |
Change
0.115(0.70%) |
Mkt cap ! $5.529B | |||
| Open | High | Low | Value | Volume |
| $16.50 | $16.86 | $16.02 | $22.42M | 1.363M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 44 | $16.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.58 | 653 | 7 |
View Market Depth
| Last trade - 14.22pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$16.58 |
Change
0.115 ( 0.08 %) |
||||
| Open | High | Low | Volume | ||
| $16.49 | $16.86 | $16.02 | 259183 | ||
| Last updated 14.39pm 14/06/2024 ? | |||||
| TLX (ASX) Chart |